Showing 61-70 of 131 results for "".
- PD1 Blocker Shrinks Advanced Squamous Cell Skin Cancershttps://practicaldermatology.com/news/pd1-blocker-shrinks-advanced-squamous-cell-skin-cancers/2457737/A checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of squamous cell carcinoma, an international team reports in the New England Journal of Medicine. “These results mark a potential paradigm shift in the treatment of patients with advanced cutaneou…
- Is a Topical Gel Made From Oral Blood Pressure Drugs a Panacea for Wound Healing, Wrinkles and More?https://practicaldermatology.com/news/is-a-topical-gel-made-from-oral-blood-pressure-drugs-a-panacea-for-wound-healing-wrinkles-and-more/2457989/Topical gel made from angiotensin II receptor blockers may speed the healing of chronic skin wounds in mice and pigs, Johns Hopkins researchers report. The findings, published in the Journal of Investigative Dermatology, marks efforts to seek approval from the U.S. Food and Drug Administration (FD…
- Consumer Reports IDs Teaching Hospitals That Expose Patients to Central Line Infectionshttps://practicaldermatology.com/news/consumer-reports-ids-teaching-hospitals-that-expose-patients-to-central-line-infections/2458366/Too many teaching hospitals are still exposing patients to dangerous bacteria via central line infections, according to Consumer Reports. The new report identifies 31 U.S. teaching hospitals on its lowest-performing “zero tolerance” list and 32 on its list of top performers. About 650,000 people …
- ARCA biopharma and Oruka Therapeutics Announce Merger Agreementhttps://practicaldermatology.com/news/arca-biopharma-and-oruka-therapeutics-announce-merger-agreement/2462611/ARCA biopharma and Oruka Therapeutics, a privately held biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, announced on April 3, 2024, that they have entered into a definitive agreement to combine t…
- FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with DEBhttps://practicaldermatology.com/news/fda-approves-first-topical-gene-therapy-for-treatment-of-wounds-in-patients-with-deb/2461732/The U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gen…
- Practical Considerations in Pediatric Alopeciahttps://practicaldermatology.com/news/practical-considerations-in-pediatric-alopecia/2461950/Hair loss in children encompasses a wide spectrum of conditions that may be congenital or acquired. Hair consists of the proteinaceous shaft and the root, anchored in the follicle, an involution of the epidermis.1 Newborn follicles produce soft lanugo hair, which is replaced by downy, fine vellus h…
- Cynosure Taps New CEOhttps://practicaldermatology.com/news/cynosure-taps-new-ceo/2461676/Nadav Tomer is Cynosure’s new chief executive officer, effective May 1, 2023. He succeeds Todd Tillemans, who will step down and will work closely with Mr. Tomer to ensure a smooth transition. "Nadav has an incredibly strong track record of operational execution in the medical technology space, …
- ASDSA's 2022 Top Advocates Recognizedhttps://practicaldermatology.com/news/asdsas-2022-top-advocates-recognized/2461381/Meet the American Society for Dermatologic Surgery Association (ASDSA) honorees from the fourth annual Top Advocate program Honorees are chosen based on their contribution to various advocacy efforts throughout the year and demonstrated commitment to patient safety in the field of dermatologic sur…
- Cynosure Upgrades PicoSure System with PicoSure Pro Devicehttps://practicaldermatology.com/news/cynosure-upgrades-picosure-system-with-picosure-pro-device/2461220/Cynosure is launching the PicoSure Pro device, the latest upgrade to the company's PicoSure system. An FDA-cleared 755nm picosecond laser, the PicoSure Pro device uniquely delivers energy in a trillionth of a second, utilizing pressure instead of heat to provide safe and effective treatments for …
- Cynosure Scores $60 Million Follow-on Investment from Clayton, Dubilier & Ricehttps://practicaldermatology.com/news/cynosure-scores-60-million-follow-on-investment-from-clayton-dubilier-rice/2461199/Cynosure, LLC, received $60 million from lead investor Clayton, Dubilier & Rice. The new capital supports the company's plans to continue investing ahead of strong growth to bring innovation to the market and provide comprehensive treatment solutions to its customers that deliver the highest clin…